Organix Inc. co-invented a number of synthetic cannabinoids for research and development purposes. Some of those are:
| Name | Class | Ki at CB1 [nM] | Ki at CB2 [nM] | Selectivity | CLogP | Structure |
|---|---|---|---|---|---|---|
| O-774 | Class 0 | 0 ± 0 | 0 ± 0 | CB0 (0.0x) | 
| |
| O-1057 | Class 0 | 0 ± 0 | 0 ± 0 | CB0 (0.0x) | 
| |
| O-1812 | Class 0 | 0 ± 0 | 0 ± 0 | CB0 (0.0x) | 
| |
| O-1991[1] | Class 0 | 30 ± 13 | 1.4 ± 0.2 | CB2 (21x) | 
| |
| O-1993[1] | Class 0 | 70 ± 10 | 86 ± 7 | CB1 (1.2x) | 
| |
| O-2050[1] | Class 0 | 2.5 ± 0.4 | 0.2 ± 0.1 | CB2 (12.5x) | 
| |
| O-2113 | Class 0 | 0 ± 0 | 0 ± 0 | CB0 (0.0x) | 
| |
| O-2372 | Class 0 | 0 ± 0 | 0 ± 0 | CB0 (0.0x) | 
| |
| O-2545 | Class 0 | 0 ± 0 | 0 ± 0 | CB0 (0.0x) | 
| |
| O-2694 | Class 0 | 0 ± 0 | 0 ± 0 | CB0 (0.0x) | 
|
- ^ a b c Wiley, Jenny L; Breivogel, Christopher S; Mahadevan, Anu; Pertwee, Roger G; Cascio, Maria Grazia; Bolognini, Daniele; Huffman, John W; Walentiny, D. Matthew; Vann, Robert E; Razdan, Raj K; Martin, Billy R (2011). "Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB1 receptor antagonist". European Journal of Pharmacology. 651 (1–3): 96–105. doi:10.1016/j.ejphar.2010.10.085. PMC 3034309. PMID 21114999.